Actions
Pages
Subscribe for newsletter
Stories
AWS has acquired Talen Energy's Cumulus Data data center campus in Pennsylvania for $650 million, which is located at a nuclear power station and includes all the land, power infrastructure, and intangibles.
AWS plans to develop up to a 960MW data center campus in northeast Pennsylvania, with two 10-year extension options tied to nuclear license renewals and minimum contractual power commitments that ramp up in 120 MW increments.
Talen Energy will supply AWS with direct-connect, carbon-free power for the data center campus, and under a separate agreement, Talen will also receive additional revenue from AWS related to sales of carbon-free energy to the grid.
Talen Energy, founded in 2015, established Cumulus Growth in 2020, comprising Cumulus Data for hyperscale data centers and Cumulus Coin for digital currency mining.
There are numerous synergies between datacenter infrastructure and cryptocurrency mining sites, so similar acquisitions are likely to occur in the future.
AWS's acquisition of a nuclear-powered data center campus underscores the tech industry's shift towards sustainable energy solutions, with significant implications for the future of data center operations and green energy adoption.
While nuclear power offers a carbon-free energy source, concerns about nuclear waste and safety remain, highlighting the need for continued innovation in sustainable energy technologies.
Story
The biotech industry is witnessing a revival in the early months of 2024 with a series of IPOs worth around $100 million or more and startup financings. This uptick, along with the recovery of biotech’s flagship stock funds and a surge in dealmaking, has sparked optimism about the industry's health.
The recent success stories include companies like CG Oncology, Kyverna Therapeutics, and ArriVent Biopharma, which not only raised more funds than anticipated but also saw their stock prices increase post-IPO. Biotech venture capital has pulled in approximately $15 billion annually in the last two years.
Invivo Partners, a Barcelona-based venture capital firm, is close to securing a new fund of €100 million ($109 million), with a potential to extend up to €120 million, marking its third fund since inception. The firm has conducted notable acquisitions like Sanifit Therapeutics by Vifor Pharma for €205 million and Versantis by Genfit for about €43 million.
However, the sustainability of this IPO resurgence remains uncertain. Following a brisk period of activity in late January and early February, no new IPO plans have been announced.
Observers are cautiously watching whether this initial burst will translate into sustained growth for the sector or if it represents a temporary spike in a typically volatile market landscape.
The IPO slowdown since late 2021 has had a cascading effect on venture funding for biotech startups, making it more challenging to raise funds at desirable valuations.
The focus on late-stage, de-risked investments raises questions about the financing landscape for early-stage biotech innovators and whether a shift in investor sentiment could broaden the pool of IPO candidates.
This current wave of investment aligns with a broader investor thesis that views biotech as a ripe area for growth, driven by technological advancements and an increasing demand for healthcare innovation.
Story
Terran Orbital’s $15 million contract for hardware and integration services to support U.S. Space Force experiments enhance the capabilities of national security satellites and defense capabilities.
This partnership exemplifies how emergent technologies can bolster the U.S. defense infrastructure, ensuring a competitive edge in space. It underscores the vital role of innovation in national security and the increasing reliance on small satellites for versatile, cost-effective solutions in space exploration and defense.
The contract was facilitated by Axient Corp, acting on behalf of the Air Force Research Laboratory (AFRL), to manage small-satellite military experiments following their own contract win in September 2023.
This announcement comes on the heels of Lockheed Martin’s proposal to acquire Terran Orbital a few days earlier. Lockheed Martin already owns a significant stake - over $500 million - in the company.
"Terran Orbital's partnership with the U.S. Space Force signifies a pivotal moment in our quest for superior space capabilities, ensuring our readiness and strategic advantage in an increasingly contested domain," remarked Marc Bell, CEO of Terran Orbital.
Delivery of the Ambassador platforms is expected within 12 months, aligning with the technologies used for the Space Development Agency’s Tranche 1 Transport Layer satellites. The successful deployment and operation of these satellites could lead to further contracts and solidify Terran Orbital's position as a key player in defense and commercial space missions.
Story
Innovators
Scroll
Open
Close